Cargando…

Betamethasone (Veterinary Medicinal Products)

The Food Safety Commission of Japan (FSCJ) conducted a risk assessment of betamethasone (CAS No. 37-44-9), a synthetic adrenocortical hormone, based on the documents including assessment reports from the European Medicines Evaluation Agency (EMEA). Among results of various studies, a no-observed-adv...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Food Safety Commission, Cabinet Office, Government of Japan 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329914/
https://www.ncbi.nlm.nih.gov/pubmed/32626636
http://dx.doi.org/10.14252/foodsafetyfscj.D-20-00016
_version_ 1783553000374009856
collection PubMed
description The Food Safety Commission of Japan (FSCJ) conducted a risk assessment of betamethasone (CAS No. 37-44-9), a synthetic adrenocortical hormone, based on the documents including assessment reports from the European Medicines Evaluation Agency (EMEA). Among results of various studies, a no-observed-adverse-effect level (NOAEL) of betamethasone (as betamethasone dipropionate) was shown as 0.02 mg/kg bw per day in a fertility and early embryonic development study in rats. FSCJ concluded that it is appropriate to set an acceptable daily intake (ADI) of betamethasone by applying the same ADI as dexamethasone. The ADI for dexamethasone at 0.01 μg/kg bw per day (0.00001 mg/kg bw/day) was specified based on the NOAEL of 0.001 mg/kg bw per day of the endocrine toxicity study in rats(1)). Consequently, FSCJ specified the ADI for betamethasone at 0.01 μg/kg bw per day.
format Online
Article
Text
id pubmed-7329914
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Food Safety Commission, Cabinet Office, Government of Japan
record_format MEDLINE/PubMed
spelling pubmed-73299142020-07-02 Betamethasone (Veterinary Medicinal Products) Food Saf (Tokyo) Risk Assessment Report The Food Safety Commission of Japan (FSCJ) conducted a risk assessment of betamethasone (CAS No. 37-44-9), a synthetic adrenocortical hormone, based on the documents including assessment reports from the European Medicines Evaluation Agency (EMEA). Among results of various studies, a no-observed-adverse-effect level (NOAEL) of betamethasone (as betamethasone dipropionate) was shown as 0.02 mg/kg bw per day in a fertility and early embryonic development study in rats. FSCJ concluded that it is appropriate to set an acceptable daily intake (ADI) of betamethasone by applying the same ADI as dexamethasone. The ADI for dexamethasone at 0.01 μg/kg bw per day (0.00001 mg/kg bw/day) was specified based on the NOAEL of 0.001 mg/kg bw per day of the endocrine toxicity study in rats(1)). Consequently, FSCJ specified the ADI for betamethasone at 0.01 μg/kg bw per day. Food Safety Commission, Cabinet Office, Government of Japan 2020-06-26 /pmc/articles/PMC7329914/ /pubmed/32626636 http://dx.doi.org/10.14252/foodsafetyfscj.D-20-00016 Text en ©2020 Food Safety Commission, Cabinet Office, Government of Japan http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Risk Assessment Report
Betamethasone (Veterinary Medicinal Products)
title Betamethasone (Veterinary Medicinal Products)
title_full Betamethasone (Veterinary Medicinal Products)
title_fullStr Betamethasone (Veterinary Medicinal Products)
title_full_unstemmed Betamethasone (Veterinary Medicinal Products)
title_short Betamethasone (Veterinary Medicinal Products)
title_sort betamethasone (veterinary medicinal products)
topic Risk Assessment Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329914/
https://www.ncbi.nlm.nih.gov/pubmed/32626636
http://dx.doi.org/10.14252/foodsafetyfscj.D-20-00016
work_keys_str_mv AT betamethasoneveterinarymedicinalproducts